CS Group (OTCQB: CSDX) announced the appointment of Shah Teelani & Associates, a PCAOB-registered audit firm based in Dubai, to consolidate and audit all 2025 financial statements for CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH. This engagement underscores the Group's commitment to strengthening financial governance, regulatory compliance, and transparency as it advances its international expansion strategy across the United States, the GCC region, and Europe.
Under the engagement, Shah Teelani & Associates will oversee the consolidation of financial statements for the three entities, which include operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion. Management stated that appointing a PCAOB-registered audit firm is a significant step in aligning the Group's financial reporting structure with U.S. public company standards while integrating its growing international companies under a unified reporting framework. The consolidated audit is expected to support enhanced financial clarity, streamlined reporting processes, and strengthened investor confidence.
Mohammad Essayed, Group Chief Financial Officer, commented: “Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group’s evolution as a publicly traded company. As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy.”
The appointment comes as CS Group continues to focus on expanding its manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap. The 2025 consolidated financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion.
CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology company advancing a dual-focus platform across infection control and oncology, targeting high-priority global healthcare markets. The Company’s portfolio includes MEDUSA, a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations for institutional and consumer use, and CS Protect-Hydrogel, a tissue spacer designed to protect healthy organs during prostate cancer radiotherapy. CSDX is progressing through key commercialization milestones, including strategic manufacturing partnerships, multi-region launches across the GCC and Europe, diversified B2B and B2C distribution channels, global logistics agreements, and a growing intellectual property and regulatory roadmap.
For further information, please visit https://group-csd.com/.
